Skip to main content

Additional Reviews & Approvals

Health and Safety are top priorities at UCSD

EH&S | Environmental Health & Safety- Radiation Specific Information

Radiation Safety

Management

Corey Singleton, CHP

Corey Singleton, CH
Radiation Safety Officer – Manage UC San Diego's Radiation Safety Programs. After hours emergency responder.

Phone: (858) 822-4045 Cell: (858) 583-3268 FAX: (858) 822-7763 E-mail: csingleton@ucsd.edu Mail Code: 0091 Office location: University Center 401, Room 103


 Scott Langford, M.S.
Scott Langford, M.S.

Alternate Radiation Safety Officer – Operational management for clinical and research radiation safety at all UCSD locations. After-hours emergency responder.

Phone: (858) 534-1066 Cell: (858) 583-3281 FAX: (858) 822-7763 slangford@ucsd.edu

Office: Pepper Canyon Hall, Room 421


 Christine Ng
Christine Ng

Radiation Safety Assistant– Manage the Radiation Use Authorization program and provide administrative support for the Radiation Safety Division.

Phone: (858) 822-2494 FAX: (858) 822-7763 E-mail:c9ng@ucsd.edu Mail Code: 0091 Office location: University Center 401, Room 106

 

Radiation Risk Calculator

  1. Go to My Research Safety.
  2. Click the Radiation Risk Statement Calculator tab.
  3. Follow instructions to enter your data. The calculator guides you through the process of accounting for the studies in your protocol.
    • Account for:
      • Only the first 12 months in your calculations and explanations of risk if a study runs longer than 12 months or for multiple years
      • Exposure to radiation from imaging studies considered standard of care, including those that would be done even if the participant were not taking part in a research protocol
  4. Click Create Statement and the calculator will generate:
    • Total exposure for the mix of studies entered
    • A risk statement explaining that exposure

Important: A generic risk statement is generated which you may or may not need to modify to clarify the situation being described. In order to assist with this process, certain parts will be emphasized in bold text to draw your attention to where your personal input will be necessary. The generic risk statement should not be directly cut and pasted into your research plan without appropriate adjustments being made.

Use the calculator's risk statement on your application forms

When submitting a project application, explanations of radiation exposure must appear in 2 places. Copy and paste appropriate portions of the risk statement generated by the calculator into the correct sections as follows:

  1. UCSD Human Research Protections Program (HRPP) New Biological Application Research Plan - Place risk information in Section 14 - Risks of Participation. If using an older form, this may be Section 13 - Potential Risks.

    • Include a summation of the examinations to be used, noting the exposure in millisieverts (mSv) that is calculated.

    • Note: If there is the possibility of other required studies based on clinical situations that arise, summarize and include an explanation of why they may be needed.

    • For complicated protocols with many imaging studies, it is useful to display this information in a spreadsheet. (See the example below.)

    • Submit documentation with your dose calculations describing how you derived your numbers.

      • Note: Best practice is to submit documentation from the UCSD Radiation Risk Statement Calculator. If Radiation Risk Statement Calculator documentation is not used, please identify the source of your numbers.

  2. Insert the Consent to Act as a Research Subject - The University of California, San Diego Consent to Act as a Research Subject is where you insert the consent statement generated by the Radiation Risk Statement Calculator. This is a concise statement showing only the total exposure with the proper supporting explanations. This section should not be as detailed as #1 above.

 

Example of spreadsheet format:

This study involves radiation exposure from diagnostic procedures that are according to standard of care and for research purposes.

The scans planned at screening are necessary per usual course of diagnostic workup and follow up per standard of care.

The intervention tested in this study does not involve additional radiation exposure.

IV contrast may be used with MRI or CT, unless contraindicated. If contrast is contraindicated, a non-contrast scan will be performed.

Note: CT scans of affected lymph node chain will only be performed if lymphadenopathy is detected by palpation.

The principal radiation exposures that are according to standard of care are:
 
 •  Chest x-ray at screening: 0.4 mSv
 •  CT Scan (Chest/Abdomen/Pelvis) IF done at screening: 13.0 mSv
 
The principal radiation exposures that are according to research purposes in this study are:
 
 •  Chest x-ray at follow up: 0.4 mSv
 
 •  CT Scan (Chest/Abdomen/Pelvis) IF done at the following points:
      • Cycle 2 / Day 1: 13.0 mSv
      • Cycle 4 / Day 1: 13.0 mSv
      • Cycle 6 / Day 1: 13.0 mSv
      • Follow up: 13.0 mSv
 

The best-case scenario would be:

Chest x-ray at screening: 0.4 mSv

NO CT Scans

This would total 0.4 mSv

The worst-case scenario would be:

Chest x-ray at screening and at follow up: 0.8 mSv

CT Scans at all points for a total of 4 CT Scans: 65 mSv

This would total: 65.8 mSv

For unique situations, write your own explanation

Deriving an explanation of exposure and risk is not always easy. For example, a protocol may call for an imaging study based on the clinical judgment of the investigator or attending physician, so the study may or may not be performed.

For unique situations:

  • Write your own explanation of the risks of radiation exposure.
  • Read examples that demonstrate how to handle 3 situations other researchers have encountered, ranging from an uncomplicated protocol to a more complex situation.
  • Follow the guidelines below:
    • Keep it simple, using wording and comparisons customary at UCSD.
    • Reference all exposure statements to typical yearly background radiation in San Diego, which is given as 1.6 mSv.
      • Do not make statements comparing the amount of radiation to some percentage of background or a number of cross-country plane flights.
    • Calculate your radiation exposure estimates for both "typical" and "worst case" scenarios when computing exposure from studies to be performed where the actual number of studies is not definite

 

Radiation Use

Requirements

Principal investigators (PIs) submitting research protocols to the Human Subjects Institutional Review Board (Office of IRB Administration) that expose human subjects to ionizing radiation must:

  • Include an explanation of the risks of radiation exposure
  • Inform study participants of the degree of risk involved (via the Informed Consent document)

These are requirements of UC San Diego's Office of IRB Administration and Human Exposure Review Committee (HERC).

Prepare and review

Before calculating radiation risk, note the following:

  • All radiation exposure is dealt with cumulatively.
  • When calculating exposure, no distinction is made between routine studies and studies done specifically for the research protocol.
  • Research protocols requiring exposure to radiation from imaging studies considered standard of care, including those that would be done even if the participant were not taking part in a research protocol, must be accounted for and exposure estimates and risks must be explained.

Calculate your project's radiation risk

Use the UCSD Radiation Risk Statement Calculator to generate a risk statement and risk category for your project. By appropriately cutting and pasting the risk statement into the correct sections of your research plan, radiation exposure risk requirements can be met.

 

Safety Committee Resources

UCSD IRB Reporting

The Principal Investigator is responsible for submitting to the IRB ongoing reports of events that may adversely affect the safety of participants or the conduct of the research, and any information relevant to the conduct of the approved research. The types of events and information that may need to be reported to the IRB include, but are not limited to:

  • Adverse Events
  • Violations, Deviations, and Incidents
  • Updated Study Safety Information

An unanticipated problem is an event or outcome that meets the following criteria: 1) unexpected; 2) related or possibly related to participation in the research; and 3) places subjects or others at a greater risk of harm than was previously known or recognized. All unanticipated problems need to be reported to the IRB via webIRB, though not all adverse events, violations, incidents or deviations are unanticipated problems. For details, please see the IRB Handbook (pg. 26-27). 

UCSD Environment, Health & Safety

Training & Outreach. In-class and online training courses are available to assist you in meeting regulatory training requirements along with videos, publications and other resources to help promote safety on campus.

Forms and Templates. Additional resources, including sample forms, templates, and examples are available via the UCSD EH&S Blink website.

HERC | Human Exposure Review Committee

As a subcommittee of the Radiation Safety Committee, this committee reviews all uses of radioactive materials or radiation-producing equipment that result in exposure to human subjects. 

This subcommittee of the Radiation Safety Committee (RSC) reviews all uses of radioactive materials or radiation-producing equipment that result in exposure to human subjects.

Members are charged with assuring all such uses are within regulatory requirements, and that a net benefit results from the radiation exposure. Physiological studies which involve radioactive drug usage as defined in 21 CFR 361.1 are referred to the Radioactive Drug Research Committee for approval.

A quorum, necessary to conduct business, consists of 4 members to include the radiation safety officer. Meetings are held as necessary to review and conduct the business of the committee, with at least 1 meeting per calendar quarter.

Contact info: 858-822-2494   |   herc@ucsd.edu

 

Radiation Exposure Calculator

Ex officio Departments
Belezzuoli, Ernest (Chair) Radiology/ Nuclear Medicine
Langford, Scott Alternate RSO, Environment, Health & Safety
Singleton, Corey Radiation Safety Officer (RSO), Environment, Health & Safety
Appointed Departments
Hall, David Radiology
Kim, Grace Radiation Medicine
Pichika, Rama Radiology
Rice, Roger Radiation Medicine
Scanderberg, Daniel Radiology
Theilmann, Rebecca Radiology
Yen, Andrew Radiology

 

IRB Research Plan Requirements

In each protocol that involves the use of radiation - whether therapeutic or diagnostic scan(s) - requires an outline of the proposed use of radiation in the OIA research plan.

Use the Radiation exposure calculator to compute the total Effective Dose Equivalent for your study. Enter the appropriate scans and click [Create Statement] and a worksheet for computation of total Effective Dose Equivalent will be provided. For assistance on using the Dose Calculator, contact herc@ucsd.edu

Tips for including the use of radiation in your protocol. The following pieces of information are required in the Radiation Exposure Section:

  • An itemized list of each type of scans showing the total for the first and each subsequent year of participation.
    • Example:
      • Year 1: 7(including screening) chest/abdomen/pelvis CTs (13mSv /scan) = 91mSv
      • Year 2: 6 chest/abdomen/pelvis CTs (13mSv/scan) = 78mSv
      • Frequency is every other cycle. Each cycle is 30 days.
  • If there are different types of scans (i.e. MUGA, chest x-ray, PET/CT, etc.), they should all be itemized to show a total radiation exposure of the first and each subsequent year of participation.
  • All diagnostic radiation exposures must show units in milliSivert (mSv).
  • If there are radiation therapy in the protocol additional language and radiation dose will need to be added after the diagnostic section.
    • Example:
      • In addition, as a participant of this protocol you will undergo radiation therapy with an overall dose of 28.5Gy in 5 fractions of 5.7Gy each.

Consent Form Requirements

Below is the HERC consent form language. The areas highlighted in yellow will need to be modified for the needs of each protocol:

Scenarios that require additional language changes to the consent:

  • If the protocol is a multi-year study the radiation language should show the total exposure for the first and each additional year of participation.
  • If a non-radiation procedure is an optional, add the following language to the second paragraph after the first sentence:
    • Radiation exposure may be decreased if non-radiation imaging alternatives are utilized, such as ECHO instead of MUGA and/or an MRI instead of a CT.
  • If radiation therapy is in the protocol, then additional language will need to be added. This should go after the consent statement:
    • Example:
      • In addition, as a participant of this protocol you will undergo radiation therapy with an overall dose of 28.5Gy in 5 fractions of 5.7Gy each.

Radiation Exposure Calculator

If you should need additional information or have questions, please contact HERC at 858-822-2494" or via email herc@ucsd.edu

RDRC | Radioactive Drug Research Committee

As a subcommittee of the Radiation Safety Committee, the major responsibility of this committee is to provide authorization, surveillance, and oversight to the use of radioactive drugs in human subjects.
Ex officio Department
Langford, Scott Alternate RSO, Environment, Health & Safety
Singleton, Corey Radiation Safety Officer (RSO), Environment, Health & Safety
Appointed Department
Belezzuoli, Ernest (Chair) Radiology/Nuclear Medicine
Nelson, Thomas Radiology
Pichika, Rama Radiology
Vera, David Radiology

Charge to committee:

This committee is to provide authorization, surveillance, and oversight to the use of radioactive drugs in human subjects. The committee is a subcommittee of, and reports to the Radiation Safety Committee, but operates under approval of the Food and Drug Administration (FDA) according to Part 361 of Title 21 of the Code of Federal Regulations.

Meetings will be held as necessary to review and conduct the business of the committee, with at least 1 meeting per calendar quarter.

A quorum of this committee, consisting of at least 4 members, including the Radiation Safety Officer, is necessary to conduct business.

The chair of this committee shall also serve as an ex officio member of the Radiation Safety Committee.

SCRO | Stem Cell Research Oversight

Stem Cell Research Oversight Committee (SCRO) – The SCRO 1) provides oversight of all issues
related to derivation and use of human adult and embryonic stem cell lines; 2) reviews and approves the
scientific merit of research protocols; 3) reviews compliance of all human adult and embryonic stem cell
research with all relevant regulations and guidelines; and 4) facilitates education of investigators involved in human adult and embryonic stem cell research. You are required to identify, in Kuali IRB, all human adult and embryonic stem cell studies. The SCRO is administered by OIA, and the electronic submission for SCRO is combined with the IRB submission in Kuali IRB to facilitate parallel review between the two committees, when necessary.

 

The Office of IRB Administration (OIA) administers the SCRO review process. For information about procedures for review of research involving covered stem cell lines requiring SCRO review, please contact irb@ucsd.edu | (858) 246-4777

For other stem cell research information, please contact these resources:

IBC | Institutional Biosafety Committee

The Institutional Biosafety Committee (IBC) advises the Chancellor through the Vice Chancellor – Resource Management & Planning on all matters relating to the safe use of hazardous biological materials and organisms.

The IBC establishes, monitors and enforces policies and procedures which meet or exceed applicable norms or regulations for biohazardous materials and/or recombinant DNA, including gene transfer clinical trials. Any use of biohazardous materials and/or recombinant DNA must be reviewed and approved by the IBC (or the Biological Safety Officer operating within guidelines established by the IBC).

The IBC has the authority to impose disciplinary measures in cases where there is willful or negligent violation of UC San Diego's established biosafety practices and procedures. Sanctions are subject to review and/or modification by the Chancellor. The IBC shall maintain diverse membership representing the community and a variety of university interests. Non-committee faculty or staff with a particular expertise will be asked to advise the committee when the need arises.

Principal investigators, follow these instructions for gene transfer clinical trial submission to UC San Diego's Institutional Biosafety Committee.

National Institutes of Health (NIH) Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules is the definitive reference for rDNA research in the United States and has been adopted by UC San Diego.

It is the principal investigator's responsibility to ensure ALL regulations and requirements are met.

Contact EH&S Biosafety with any questions.

PRMC | Protocol Review & Monitoring Committee

About

The Protocol Review and Monitoring Committee (PRMC) is a multidisciplinary standing committee of the Moores Cancer Center at UC San Diego Health. The PRMC is responsible for the scientific peer review of cancer-related research protocols conducted at UC San Diego Health and/or its affiliate institutions (e.g. the Veterans Administration San Diego Healthcare System and Rady Children's Hospital San Diego). The PRMC is also responsible for monitoring the scientific conduct of institutional cancer clinical trials as required by the National Cancer Institute (NCI).

The PRMC reviews research protocols to be conducted at UC San Diego Health and/or its affiliate institutions that involve:

  • Subjects with cancer
  • Biological specimens from cancer patients 

The PRMC is granted authority by the Moores Cancer Center Director to:

  • Approve cancer-related research protocols for activation at UC San Diego Helath and affiliate sites
  • Issue binding recommendation for protocol modification or amendment for scientific validity or subject safety
  • Defer activation of protocols due to deficiencies in content, design, feasibility
  • Recommend closing protocols that show unsatisfactory accrual or scientific progress by predetermined time points after activation, usually coincident with annual Continuing Review

Please contact the PRMC for access to the PRMC Protocol Review List for the studies that require or are exempted from the PRMC review. 

 

Submission Requirements

The PRMC requires the following documents for the initial review:

  • Cover Memo
  • Disease Approval Form (for intervention trials) 
  • Research Plan
  • Biomedical Face Page (signature not required)
  • Master Protocol
  • Package Insert (for the FDA approved drugs)
  • Investigator's Brochure
  • FDA Correspondence (for Investigator Initiated Trials)

The required documents should be submitted to the PRMC using the webpage https://oncline.ucsd.edu/PRMC. To request an ePRMC account please use the following link: https://oncline.ucsd.edu/PRMC/Request1.asp. For information regarding setting up a user account and instructions for submitting a new protocol, uploading documents to an existing protocol, checking the approval status of a submission and more, review the ePRMC User Manual. The ePRMC User Manual is available on the ePRMC website once logged in.

For frequently asked questions, see the ePRMC FAQs.

For additional information about ePRMC document submission policies and procedures, please contact the PRMC office: 858-657-5924  |  858-657-5925   |  prmc@ucsd.edu

 

Review Schedule

  • Protocols subject to PRMC review should be submitted to the PRMC

  • The protocols are reviewed in order of the submission date to the PRMC

  • PRMC meetings occur twice monthly on the first and third Tuesday from 5:00-7:00 PM.

 

Decisions and Actions

Industry-sponsored and institutional protocols are presented at PRMC meetings.  The Principal Investigator (PI) receives an invitation 14 days prior to the meeting date.  When all presenters confirm their participation, the protocol will receive an exact time slot for presentation.  The PI receives a Power Point template that contains all necessary information the PRMC requires for review and helps to maintain a time limit of 4 minutes for the presentation. PRMC determination is sent to the PI within 2 business days after the meeting.
  • If a study is voted "Approve Pending", the investigator's response submission is reviewed administratively
  • If the study is "Deferred", the investigator's response and appropriately revised study documents must be submitted for review at a convened PRMC meeting.

 

Amendments

The PRMC reviews amendments to previously approved protocols that meet the following criteria:

  • significant change to eligible subject population

  • significant change in study design that impacts the analysis of data (includes major increase in sample size, adding or dropping a study arm, etc.)

  • change to study-related procedures that significantly increases risk to subjects

 

PRMS | Protocol Review and Monitoring System

The overall goal of the Protocol Review and Monitoring System (PRMS) is to promote the conduct of scientifically meritorious clinical research under the aegis of the Moores Cancer Center. The mechanism for accomplishing this goal is the establishment of a Protocol Review and Monitoring Committee (PRMC) to provide internal oversight of all clinical and translational research involving subjects with cancer, as required by the National Cancer Institute.

Through specified procedures for protocol scientific review, prioritization approval, and monitoring of clinical trial progress and conduct, the PRMC ensures that MCC resources are effectively utilized to foster clinical cancer research that is of high scientific quality and importance.

The PRMC retains the authority granted by the Center Director to:

  • Approve cancer-related research protocols for activation at UCSD and affiliate institutions

  • Issue binding recommendations for protocol modification or amendment for reasons of scientific validity or subject safety

  • Defer activation of protocols due to deficiencies in content, study design, or feasibility

 

Resources

 

Contacts

ePRMC

prmc@ucsd.edu 

(858) 657-5924  |  (858) 657-5925  

Location: SOM/East Campus MCM1, Office 111
Mail Code: 0880